A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis

Clinical trial NCT05676242 · UNKNOWN

Trial details

NCT number: NCT05676242
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Atopic Dermatitis

Start date: 2023-01-11
Primary completion: 2024-12-01
Enrollment: 400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.